| Literature DB >> 26471370 |
Sandra Mercier1,2,3, Sébastien Küry4, Emmanuelle Salort-Campana5, Armelle Magot6,7, Uchenna Agbim8, Thomas Besnard9, Nathalie Bodak10, Chantal Bou-Hanna11, Flora Bréhéret12, Perrine Brunelle13, Florence Caillon14, Brigitte Chabrol15, Valérie Cormier-Daire16, Albert David17, Bruno Eymard18, Laurence Faivre19,20, Dominique Figarella-Branger21, Emmanuelle Fleurence22,23, Mythily Ganapathi24, Romain Gherardi25, Alice Goldenberg26, Antoine Hamel27, Jeanine Igual28, Alan D Irvine29,30,31, Dominique Israël-Biet32, Caroline Kannengiesser33, Christian Laboisse34,35, Cédric Le Caignec36, Jean-Yves Mahé37,38, Stéphanie Mallet39, Stuart MacGowan40,41, Maeve A McAleer42,43, Irwin McLean44, Cécile Méni45, Arnold Munnich46, Jean-Marie Mussini47, Peter L Nagy48, Jeffrey Odel49, Grainne M O'Regan50, Yann Péréon51,52, Julie Perrier53, Juliette Piard54, Eve Puzenat55, Jacinda B Sampson56, Frances Smith57, Nadem Soufir58, Kurenai Tanji59, Christel Thauvin60,61, Christina Ulane62, Rosemarie M Watson63, Nonhlanhla P Khumalo64, Bongani M Mayosi65, Sébastien Barbarot66, Stéphane Bézieau67,68.
Abstract
BACKGROUND: Hereditary Fibrosing Poikiloderma (HFP) with tendon contractures, myopathy and pulmonary fibrosis (POIKTMP [MIM 615704]) is a very recently described entity of syndromic inherited poikiloderma. Previously by using whole exome sequencing in five families, we identified the causative gene, FAM111B (NM_198947.3), the function of which is still unknown. Our objective in this study was to better define the specific features of POIKTMP through a larger series of patients.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26471370 PMCID: PMC4608180 DOI: 10.1186/s13023-015-0352-4
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Clinical and molecular data of affected individuals affected
| Characteristics | Individual F1a | Family F2a | Individual F3a | Individual F4a | Individual F5 | Individual F6 | Individual F7 | Individual F8 | Individual F9 | Family F10a | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Origin: France | Origin: Algeria | Origin: Italy | Origin: France/Morocco | Origin: France | Origin: Ireland | Origin: Dominican Republic | Origin: France | Origin: France | South-Africa | ||||||
| Sex | M | M (proband) | M (son) | F | F | F | F | M | M | M | F (proband) | M (father) | M (brother) | M (brother) | |
| Age at last examination | 10 yrs | 32 yrs | 8 months | 13 yrs | 9 yrs | 4 yrs | 5 yrs | 23 yrs | 8 yrs | Death: 40 yrs | 26 yrs | Death: 56 yrs | Death: 30 yrs | 31 yrs | |
| Consanguinity | No | Yes | No | No | No | No | No | No | No | No | No | No | No | No | |
| General | Growth retardation/Hypotrophy (height; weight) | No | 165 cm (−1.7 SD); 40 kg (BMI:14.7) | No | 145 cm (−1.5 SD); 30 kg (BMI: 14.3) | 120 cm (−1.9 SD); 15.8 kg (BMI:11) | 102 cm (+0.2 SD); 14 kg (BMI:13.5) | 91.3 cm (−3.9 SD); 12.3 kg (BMI:14.8) | No | No | 163 cm (−2.1 SD); 53 kg (BMI:19.9) | No | No | No | No |
| Delayed puberty | n/a | Yes (17 yrs) | n/a | Yes | n/a | n/a | n/a | No | n/a | No | n/a | n/a | n/a | n/a | |
| Normal IQ | Yes | Yes | n/a | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| Psychiatric disorders | No | No | n/a | No | No | No | No | No | No | Schizophrenia | No | No | No | No | |
| Skin | Poikiloderma (early childhood) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| - Face | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| - Exposed area/photosentivity | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| - Upper and/or lower limbs | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | |
| Bullous lesions | Yes | No | No | No | No | No | Yes | No | No | No | No | No | No | No | |
| Eczema-like | Yes | Yes | Yes | No | Yes | Yes | Yes | No | No | No | No | No | No | No | |
| Ichthyosis-like | No | No | No | No | No | Yes | No | No | No | Yes | |||||
| Psoriasis-like | No | No | No | No | Yes | No | No | No | No | No | No | No | No | No | |
| Blaschko linear hypo/hyperpigmentation | No | No | No | No | No | Yes | No | Yes | No | No | No | No | No | No | |
| Lymphoedema of extremities | Yes | No | No | Yes | Yes | Yes | Yes | Yes | No | Yes | No | No | No | No | |
| Cellulitis | Yes | No | No | Yes | No | No | Yes | No | No | No | No | No | No | No | |
| Sclerosis of the digits | No | Yes | No | No | No | No | No | No | No | No | Yes | n/a | n/a | Yes | |
| Palmoplantar abnormalities | No | No | No | No | No | Palmar erythrosis and palmoplantar keratoderma | No | No | Palmar erythrosis | Palmoplantar keratoderma | |||||
| Hypohidrosis/Heat intolerance | Yes | Yes | Yes | n/a | Yes | Yes | Yes | Yes | No | n/a | Yes | Yes | Yes | Yes | |
| Hair | Hypotrichosis/Alopecia | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | n/a | n/a | Yes |
| - Scalp hair | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| - Eyebrows | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| - Eyelashes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | No | No | |
| Nails | Dysplasia | No | No | No | Yes | No | No | Yes | Yes | No | No | Yo | No | No | No |
| Muscle | Muscle weakness (Age at onset) | Yes (7 yrs) | Yes (11 yrs) | No | Yes (4y) | Yes (14 months) | No | Yes (infancy) | Yes (2 yrs) | Yes (8 yrs) | No | Yes (9 yrs) | n/a | n/a | n/a |
| - Proximal lower limbs | Yes | yes | No | Yes | Yes | No | Yes | Yes | Yes | No | n/a | n/a | n/a | n/a | |
| - Distal lower limbs | Yes | Yes | No | Yes | Yes | No | No | Yes | Yes | No | n/a | n/a | n/a | n/a | |
| - Proximal upper limbs | Yes | Yes | No | Yes | Yes | No | No | Yes | No | No | n/a | n/a | n/a | n/a | |
| - Distal upper limbs | Yes | Yes | No | Yes | Yes | No | No | Yes | No | No | n/a | n/a | n/a | n/a | |
| - Neck: extensors/Sternocleidomastoid (SCM) | No | Yes (SCM), trunk extensors, abdominal muscles | No | n/a | Yes | No | No | Yes | No | No | n/a | n/a | n/a | n/a | |
| Amyotrophy | Yes | Yes | No | Yes | Yes | No | No | No | No | No | n/a | n/a | n/a | n/a | |
| Abolition of lower limb tendon reflex | No (weak reflexes) | Yes | No | Yes | Yes | No | n/a | Yes | No | No | n/a | n/a | n/a | n/a | |
| Tendon lengthening (age) | Yes (7 yrs) | Yes (11 yrs) | No | Yes (13 yrs) | No | No | No | No | No | No | Yes (14 yrs) | No | Yes (5 yrs) | No | |
| Joints | Lower limbs contractures(Age at onset) | Triceps surae (6 yrs) | Triceps surae (7 yrs) | No | Triceps surae | Triceps surae (2 yrs) Hamstring (7 yrs) | Triceps surae (3 yrs) | Triceps surae (4 yrs) | No | Triceps surae (7 yrs) | No | Triceps surae | n/a | n/a | No |
| Triceps surae muscle/Hamstring muscle | |||||||||||||||
| Upper limb contractures | No | Biceps brachii (2–3 yrs) Carpal extensor | No | Yes | Yes | No | No | Yes (identified at age 23) | No | No | No | n/a | n/a | No | |
| Biceps brachii and carpal extensors | |||||||||||||||
| Spine | Scoliosis | No | Yes | No | Yes | No | No | No | No | No | No | No | No | No | No |
| Oral sphere | Dysphagia/Velopharyngeal insufficiency | No | Yes | No | n/a | Yes | No | No | Yes | No | No | n/a | n/a | n/a | n/a |
| Liver | Hepatomegaly | No | No | No | Yes | No | No | No | No | No | No | No | No | No | No |
| Pancreas | Steatorrhea/Exocrine insufficiency | Yes | n/a | n/a | n/a | No | Yes | Yes | Yes | No | No | n/a | n/a | n/a | n/a |
| Eye | Cataract | No | No | No | Yes | No | No | No | No | No | No | No | No | No | No |
| Other | No | No | No | No | No | No | No | Shallow orbits with mild restriction of medial rectus action OU; right macular pigmentary changes | No | Corneal thickness | No | No | No | No | |
| Blood test | SCK (UI/l) (maximum) | N | 460 | n/a | 500 | 340 | 370 | N | 372 | n/a | N | n/a | n/a | n/a | n/a |
| Blood count abnormalities (maximum) | Eosinophilia 1.5 × 10e9/L | N | n/a | N | Eosinophilia 0.8 × 10e9/L | N | Eosinophilia 0.9 x 10e9/L | PLT count: 78 x 10e9/L, MCV: 98.4 fL | N | N | n/a | n/a | n/a | n/a | |
| Liver function | n/a | N | n/a | Cholestasis | n/a | SGOT: 63 IU/L (<53); SPGT: 56 IU/L (<36); ALP: 308 IU/L (<335); GGT: 53 IU/L (<26) | SGOT:210 IU/L (<40); SGPT: 151 IU/L (<35); ALP: 772 IU/L (<315); Bili: 33 mmol/l (<14) | SGOT: 100 IU/L (<38); SGPT: 132 IU/L (<41); ALP:129 IU/L (<129); GGT:106 IU/L (<58) | n/a | n/a | n/a | n/a | n/a | n/a | |
| Muscle exploration | EMG: myogenic | Yes | n/a | n/a | Yes | Yes | n/a | n/a | N | n/a | n/a | n/a | n/a | n/a | n/a |
| MRI/CT-scan | Adiposis (MRI) | Adiposis (MRI) | n/a | n/a | n/a | n/a | n/a | Atrophy of paraspinal and rectus abdominis muscles (CT scan) | n/a | Adiposis (MRI) | n/a | n/a | n/a | n/a | |
| Lung exploration | PFT (pulmonary Function Test): Restrictive syndrome | Yes (asthma) | Yes | n/a | n/a | Yes | n/a | Yes | Yes | Yes (poor participation) | Yes | Yes | Yes | Yes | No |
| - FVC (% of predicted) | 1.61 L (83 %) | 1.82 L (42 %) | n/a | n/a | 38 % | n/a | 53 % | 64 % | 1.33 L (86 %) | 1.47 L (36 %) | 78 % | n/a | 34 % | 91 % | |
| - FEV1 (% predicted) | 1.25 L/min (73 %) | 2.02 (44 %) | n/a | n/a | n/a | n/a | 56 % | n/a | 1.32 L/min (101 %) | 1.15 L/min (34 %) | n/a | n/a | 37 % | n/a | |
| - FEV1/FCV (%) | 78 % | 111 % | n/a | n/a | n/a | n/a | N | n/a | 99 % | 78 % | 86 % | n/a | 90 % | 76 % | |
| - DLCO | n/a | 41 % | n/a | n/a | 51 % | n/a | n/a | n/a | 0.87 (64 %) | Not feasible | 67 % | n/a | 34 % | 88 % | |
| PET/CT-scan | n/a | No pulmonary fibrosis (CT scans) | n/a | n/a | No fibrosis | n/a | No fibrosis | No pulmonary fibrosis; presence of a nodule | n/a | Pulmonary fibrosis, slightly hypermetabolic lesions | n/a | n/a | n/a | n/a | |
| Pathology | Peripheral muscle | Adiposis | Dystrophy, fibrosis, adiposis | n/a | Dystrophy, fibrosis, adiposis | Fibrosis, adiposis | n/a | n/a | Fibroadipose replacement, endomysial fibrosis, atrophic and hypertrophic fibers, central nuclei | n/a | n/a | n/a | n/a | Fatty infiltration | n/a |
| Skin | Sclerodermiform aspect, Elastin anomalies | n/a | n/a | n/a | RTS-like | n/a | Hyperkeratosis, parakeratosis, hypergranulosis, acanthosis, spongiosis. Numerous apoptotic keratinocytes. | n/a | n/a | n/a | n/a | n/a | Sclerodermiform aspect, fibrosis, elastic tissue degeneration | n/a | |
| Visceral organs | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | Pulmonary fibrosis | Pulmonary, esophageal and mediastinal lymph node fibrosis, pancreas fatty infiltration | n/a | |
| Vasculature | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | Elastic degeneration, medial calcification | n/a | |
| Gene analysis |
| No mutation | No mutation | n/a | No mutation | No mutation | No mutation | No mutation | No mutation | No mutation | No mutation | n/a | No mutation | No mutation | n/a |
| Other genes | No |
|
| No |
| No | No |
| No | No | No | No | No | No | |
|
| c.1879A > G (p.Arg627Gly) | c.1879A > G (p.Arg627Gly) | c.1879A > G (p.Arg627Gly) | c.1879A > G (p.Arg627Gly) | c.1883G > A (p.Ser628Asn) | c.1883G > A (p.Ser628Asn) | c.1883G > A (p.Ser628Asn) | c.1883G > A (p.Ser628Asn) | c.1874C > A (p.Thr625Asn) | c.1289A > C (p.Gln430Pro) | c.1861 T > G (p.Tyr621Asp) | n/a | c.1861 T > G (p.Tyr621Asp) | c.1861 T > G (p.Tyr621Asp) | |
| Inheritance |
|
| Paternal inheritance | n/a | No maternal inheritance |
|
|
|
| n/a | Paternal inheritance | n/a | Paternal inheritance | Paternal inheritance | |
aIndividuals F1, proband F2, F3 and F4 were described in the initial report as individuals F1-II2, F2-II4, F3-II1 and F4-II1, respectively [6]
The following abbreviations are used: ALP alkaline phosphatase, Bili bilirubin, BMI body mass index, DLCO diffusing capacity of the lung for carbon monoxide, EMG electromyography, FEV1 forced expiratory volume, FVC forced vital capacity, GGT gamma-glutamyl transpeptidase, MCV mean corpuscular volume, N normal, n/a not available, MRI magnetic resonance imaging, PET/CT-scan positron emission tomography/computed tomography scan, PFT pulmonary function test, PLT platelet, RTS Rothmund-Thomson syndrome, SCK serum creatine kinase, SCM sternocleidomastoid muscle, SGOT serum glutamate oxaloacetic transaminase, SGPT serum glutamate pyruvate transaminase
Fig. 1Facial and scalp skin lesions. Poikiloderma and alopecia of the scalp, eyebrows, and eyelashes in individuals F1, F4, F5, F6, F8 and F9 (a-f)
Fig. 2Skin lesions of upper and lower limbs. Eczema-like and psoriasis-like dermatosis of the upper limbs in individual F4 (a); hyperpigmentated regions in individual F5 (b); chronic lymphoedema of lower limbs and hands in individuals F4 (c, d), F6 (e), F8 (f); diffuse skin lesions of lower limbs and cellulitis in individual F6 (e, g)
Fig. 3Muscle and skin microscopy. a-d Fatty tissue, fragmented muscle fascicles next to normal fascicles in individuals F1 (a-b) or nonspecific myopathic changes with variation in fiber size in proband F2 (c-d) (Hematoxylin and eosin staining [H&E]; ×20 (a) and ×100 magnification (b-d)). e-f Epidermal atrophy, scleroderma-like features with a diffuse mild collagen sclerosis (e) (individual F1; H&E; ×20 magnification); elastic dystrophy with formation of elastic globes (arrowheads) in the papillary dermis (f) (individual F1; Weigert staining; ×150 magnification)
Fig. 4Muscle MRI (coronal images: thighs (up); calves (down); T1-weighted sequence). Diffuse bright appearance of the anterior compartment of the thighs, particularly in the vastus lateralis muscles, and the posterior compartment of the calves in individual F1 at 7 years of age (a); more severe stage with a relative sparing of the posterior compartment of the thighs in proband F2 at 30 years (b). Specific involvement of the vastus lateralis muscles (asterisks) with sparing of other thigh muscles in individual F9 (c)
Fig. 5Missense variants identified in FAM111B. Conserved amino acid sequences among mammals and cluster within a putative cysteine/serine trypsin-like peptidase domain of FAM111B. Variant #1 [c.1289A > C (p.Gln430Pro)] identified in individual F9; variant #2 [c.1861 T > G (p.Tyr621Asp)] in the South-African family F10; variant #3 [c.1874C > A (p.Thr625Asn)] in individual F8; variant #4 [c.1879A > G (p.Arg627Gly)] in individuals F1, F3 and family F2; variant #5 [c.1883G > A (p.Ser628Asn) in individuals F4, F5, F6 and F7